TerminatedPhase 3NCT05178862
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Studying Invasive candidiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Scynexis, Inc.
- Principal Investigator
- David Angulo, MDScynexis, Inc.
- Intervention
- SCY-078(drug)
- Enrollment
- 68 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (30)
- University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
- Banner University Medical Center-Tucson, Tucson, Arizona, United States
- UC Davis Medical Center, Sacramento, California, United States
- UCSF School of Medicine, San Francisco, California, United States
- University of Colorado Anschutz Medical Campus, Denver, Colorado, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Ochsner Medical Center, New Orleans, Louisiana, United States
- LSU Health Sciences Center, Shreveport, Louisiana, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- University of Minnesota Medical Center, Minneapolis, Minnesota, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05178862 on ClinicalTrials.govOther trials for Invasive candidiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05421858A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.Basilea Pharmaceutica
- RECRUITINGPHASE2NCT06194201A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisFujian Shengdi Pharmaceutical Co., Ltd.
- RECRUITINGNCT06456151Invasive Candidiasis in Critical CareUniversity Hospital Ostrava
- RECRUITINGNANCT05763251Comparison of Uncomplicated Candidemia Therapy Duration in ChildrenArkansas Children's Hospital Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT04368559Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationMundipharma Research Limited
- RECRUITINGNANCT03538912Early Discontinuation of Empirical Antifungal Therapy and BiomarkersUniversity Hospital, Lille